Direct-to-consumer digital care firm Hims & Hers is the newest digital well being firm to announce it would add GLP-1 medicines to its choices to help customers with weight-loss administration.
The San Francisco-based firm, which launched its weight-loss program in December, mentioned customers will now have entry to generic and 503B compounded injectable medicines and oral treatment kits for weight administration that begin at $199 a month.
In a press release, the corporate mentioned its medicines will probably be extra available than model names like Ozempic or Wegovy due to a partnership with a U.S. producer of generic variations of GLP-1s.
“We’ve leveraged our dimension and scale to safe entry to one of many highest-quality provides of compounded GLP-1 injections accessible as we speak. We’re passing that entry and worth alongside to our prospects, who deserve the very best customary of medical security and efficacy to satisfy their objectives, and we’re doing it in a secure, inexpensive manner that others can’t ship,” Andrew Dudum, CEO and cofounder of Hims & Hers, mentioned in a press release.
THE LARGER TREND
Researchers proceed to guage the security of GLP-1 medicines for long-term use.
One research printed within the Worldwide Journal of Medical Pharmacy revealed there’s growing knowledge on the potential of pancreatic carcinoma related to GLP-1 receptor agonists.
Nevertheless, one other research printed in JAMA Community Open confirmed that researchers discovered no assist for elevated pancreatic most cancers incidence after seven years following the beginning of GLP-1 therapy.
Different corporations which have added GLP-1-focused choices to their platform embody digital chronic-condition-management firm Lark Well being.
Digital weight-loss firm Noom introduced its business enterprise, Noom for Work, and nationwide pharmacy profit supervisor Liviniti have been partnering to supply plan sponsors and their workers a digital GLP-1 Companion for continual weight circumstances.
